Kenneth Hoberman bought stock once, on May 12, 2022

Director at Nuvectis Pharma, Inc., and 1 other company

SEC CIK 0001573722 · Filings on SEC.gov ↗

$104KBought

$4.3MSold

May 16Last buy

Kenneth Hoberman's record

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Companies

Every filing

21 filings since Jan 2017, newest first

NVCTBuy

Nuvectis Pharma, Inc.

Director

$104K+12.0%May 16

STMLSell

Stemline Therapeutics Inc

COO

$130K−3.0%Mar 13

STMLSell

Stemline Therapeutics Inc

COO

$74K−1.0%Feb 28

STMLSell

Stemline Therapeutics Inc

COO

$155K−4.0%Jan 24

STMLSell

Stemline Therapeutics Inc

COO

$137K−2.0%Jan 10

STMLSell

Stemline Therapeutics Inc

COO

$502K−7.0%Jan 3

STMLSell

Stemline Therapeutics Inc

COO

$710K−6.0%Jun 28

STMLSell

Stemline Therapeutics Inc

COO

$368K−3.0%May 17

STMLSell

Stemline Therapeutics Inc

COO

$290K−3.0%Mar 15

STMLSell

Stemline Therapeutics Inc

COO

$34KMar 8

STMLSell

Stemline Therapeutics Inc

COO

$127K−1.0%Feb 27

STMLSell

Stemline Therapeutics Inc

COO

$138K−2.0%Jan 11

STMLSell

Stemline Therapeutics Inc

COO

$312K−4.0%Nov 30

STMLSell

Stemline Therapeutics Inc

COO

$514K−7.0%Mar 14

STMLSell

Stemline Therapeutics Inc

COO

$50K−1.0%Mar 9

STMLSell

Stemline Therapeutics Inc

COO

$192K−3.0%Feb 28

STMLSell

Stemline Therapeutics Inc

COO

$29KFeb 16

STMLSell

Stemline Therapeutics Inc

COO

$196K−4.0%Jan 12

STMLSell

Stemline Therapeutics Inc

COO

$170K−3.0%Dec 19

STMLSell

Stemline Therapeutics Inc

COO

$56K−3.0%Mar 1

STMLSell

Stemline Therapeutics Inc

COO

$126K−3.0%Jan 13

Filings come from SEC EDGAR. Not investment advice.